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ABSTRACT OF THESIS 
ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH VANCOMYCIN AND 
PIPERACILLIN-TAZOBACTAM: A RETROSPECTIVE COHORT ANALYSIS 
Empiric antimicrobial therapy often consists of the combination of Gram-positive 
coverage with vancomycin (VAN) and Gram-negative coverage, specifically an anti-
pseudomonal beta-lactam, such as piperacillin-tazobactam (PTZ). Nephrotoxicity is 
commonly associated with VAN therapy; however, recent reports demonstrate increasing 
nephrotoxicity rates among patients treated with the combination of VAN and PTZ. This 
study evaluated the effect of the VAN/PTZ combination on acute kidney injury (AKI), as 
defined by the RIFLE criteria, compared to VAN and PTZ monotherapies.  
Overall, 11,650 patients were analyzed, with 1,647 (14.1%) AKI cases occurring. 
AKI was significantly more frequent in the VAN/PTZ group (21%) compared to either 
monotherapy group (VAN 8.3%, PTZ 7.8%, p<0.001 for both). Combination therapy was 
independently associated with higher AKI odds compared to monotherapy with either 
agent (aOR=2.03; 95% CI 1.74-2.39; aOR=2.31; 95% CI 1.97-2.71, for VAN and PTZ, 
respectively). Receipt of concomitant nephrotoxic drugs were independently associated 
with increased AKI rates, as were increased duration of therapy, length of hospital stay, 
increasing severity of illness, and increasing baseline renal function.  
VAN combined with PTZ was associated with twice the odds of AKI 
development compared to either agent as monotherapy. This demonstrates the need for 
judicious use of combination empiric therapy. 
KEYWORDS: Antimicrobial stewardship, Vancomycin, Piperacillin-tazobactam, 
Acute Kidney Injury, Electronic health record 
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Chapter One: Introduction 
 The glycopeptide antibiotic vancomycin is commonly utilized in empiric coverage 
for methicillin-resistant Staphylococcus aureus (MRSA) in many types of infections. 
Literature from a variety of patient populations reports nephrotoxicity associated with 
vancomycin, targeting troughs greater than 15 µg/mL, to occur in 5 to 43% of patients.[1] 
In a study of critically ill patients, acute kidney injury (AKI) was found in 21% of patients 
receiving vancomycin, with increasing duration of vancomycin treatment, greater 
vancomycin levels, concomitant vasoactive medication administration, and intermittent 
infusion methods being associated with higher odds of AKI.[2] A recent report from adult 
internal medicine patients estimated the incidence of vancomycin-associated 
nephrotoxicity at 13.6% and implicated concomitant piperacillin-tazobactam therapy as a 
key factor in these patients.[3]  
 Further studies have explored the interaction between empiric beta-lactam and 
vancomycin therapy, showing mixed results. Reports of AKI associated with the 
combination of vancomycin and piperacillin-tazobactam range from 16.3 to 34.8% [4-8], 
while the cefepime-vancomycin combination is reported to range from 12.5 to 13.3%. [5,6] 
While vancomycin monotherapy groups were well represented, only one of these studies 
compared the piperacillin-tazobactam-vancomycin combination to a control group of 
piperacillin-tazobactam monotherapy.[7] 
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Chapter Two: Methods 
 This is a retrospective cohort study of adult patients conducted at the University of 
Kentucky Chandler Medical Center (UKMC) from September 1, 2010 through August 31, 
2014. Patients were included if they: were at least 18 years of age on admission; remained 
hospitalized for at least 48 hours; received vancomycin combined with  piperacillin-
tazobactam (VAN/PTZ), vancomycin alone (VAN), or piperacillin-tazobactam alone 
(PTZ); and had at least 48 hours of therapy (and 48 hours of overlapping therapy in the 
VAN/PTZ group). Patients were excluded if they had underlying chronic kidney disease, 
were receiving renal replacement therapy prior to admission, had a diagnosis of cystic 
fibrosis, or were pregnant. Additionally, patients were excluded if: they presented with 
AKI, defined as baseline creatinine clearance less than 30 mL/min, or if baseline creatinine 
clearance was greater than four times the standard deviation from the mean; serum 
creatinine values were not obtained during admission; and if AKI occurred prior to therapy 
initiation, within 48 hours of initiation, or greater than 7 days after treatment was 
discontinued. Patients were followed throughout their stay until time of discharge. 
 
Data Source 
Patient data were collected from the University of Kentucky Center for Clinical and 
Translational Science Enterprise Data Trust (EDT). The EDT contains clinical data from 
the inpatient population of UKMC from 2006 to present. Data stored and updated nightly 
by the EDT includes: demographics, financial classification (Medicare, Medicaid, private 
insurance), provider-level detail (service line), medical diagnosis (International 
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Classification of Diseases 9 [ICD-9] codes), medical procedures (Current Procedural 
Terminology [CPT] codes), lab tests and results, medication administration details, visit 
details (age, length of stay, etc.), and vital signs. This study was approved by the UKMC 
Institutional Review Board.  
Data collected for each patient included: demographic data, visit details (length of 
stay, admitting and primary diagnosis codes, etc.), severity of underlying illness as defined 
by the Charlson Comorbidity Index (CCI), all serum creatinine levels drawn per visit, 
medication administration information (dose, date, and time administered), all vancomycin 
trough levels, receipt of other nephrotoxic agents, blood pressures, and receipt of 
vasopressors. 
Outcome Ascertainment 
AKI was defined based on the RIFLE criteria (Risk, Injury, Failure, Loss, End-
stage)[9] with risk defined as a 25 to 50% decrease in estimated glomerular filtration rate 
(GFR), injury as a 50 to 75% decrease in estimated GFR, and failure defined as a greater 
than 75% decrease in estimated GFR. Loss and end-stage classifications were not assessed 
due to the follow-up period of this study. The adjusted Cockcroft and Gault equation [10] 
was used to estimate GFR due to the inconsistency of weight availability in the dataset. 
Baseline creatinine clearance was calculated with the first serum creatinine obtained, and 
the minimum creatinine clearance was calculated using the maximum serum creatinine 
during each patient’s visit; the percent decrease in creatinine clearance was calculated from 
these two values. AKI status was defined as meeting any of the RIFLE criteria. Mortality 
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was assessed for all patients and defined as the composite of in-hospital mortality and 
discharge or transfer to hospice care. 
Exposure Ascertainment 
Hypotension exposure was defined as experiencing one of the following: mean 
arterial blood pressure less than 60 mmHg, a diagnosis of hypotension by a physician, or 
receipt of vasopressors or inotropic agents. Days of therapy for each drug was obtained, 
and combination days of therapy was calculated by including only those days in which the 
patient received both medications. Total days of therapy was calculated by the sum of all 
days receiving at least one of the study agents. The average daily vancomycin dose was 
calculated for each patient by taking the sum of all vancomycin doses received and dividing 
by the days of vancomycin therapy. Exposure to other nephrotoxic agents (acyclovir, 
angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, 
aminoglycosides, amphotericin B, cyclosporine, foscarnet, loop diuretics, nonsteroidal 
anti-inflammatory drugs [NSAIDs], sulfonamides, tacrolimus, and tenofovir) was defined 
as receipt of at least one dose of the agent during hospitalization. 
Statistical Analysis 
Characteristics between groups were described with basic descriptive statistics. 
Continuous variables were compared with one-way ANOVA or the Kruskal-Wallis test. 
Categorical variables were compared with χ2 or Fisher’s exact test. Yearly AKI trends were 
assessed with Pearson’s correlation coefficient. Univariate models for all covariates were 
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created with probability of AKI as the outcome. Covariates significant after univariate were 
then incorporated into the multivariate model, which was subsequently adjusted to achieve 
the highest predictive accuracy by minimizing the Akaike information criterion (AIC). 
Model fit was assessed with a standardized Hosmer-Lemeshow goodness of fit test.[11] 
All statistical analyses were completed with RStudio v0.98 running R v3.1.2 (R Foundation 
for Statistical Computing, Vienna, Austria)[12]. All tests were two-tailed and significance 
was defined at an alpha of 0.05. 
 
Role of Funding Source 
The project described was supported by the National Center for Advancing 
Translational Sciences, National Institutes of Health, through grant number 
UL1TR000117.  The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the NIH. 
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Chapter Three: Results 
Baseline Patient Characteristics 
Of 17,879 patients initially screened, 11,650 patients were evaluated, of which 
5,497 received VAN and PTZ (VAN/PTZ), 3,055 received VAN alone, and 3,098 received 
PTZ alone (Figure 2). Table 1 contains basic demographic information. The average age 
of patients was 52.5 ± 16.8 years with 6,242 (53.6%) males. Patients receiving VAN/PTZ 
had higher CCIs than either monotherapy group and had significantly increased length of 
hospitalization. While patients in the combination therapy group were more likely to 
experience some level of hypotension, concomitant nephrotoxic agent exposure was more 
common in the VAN monotherapy group. 
7 
FIGURE 1: Patient exclusion flowchart 
Patients receiving VAN, 
PTZ, or VAN/PTZ 
N = 17,874 
- Adults ≥ 18 
- No pregnancy 
- No CF 
- No diagnosed CKD or 
dialysis
Final population 
N=11,650 
- VAN = 3,055 
- PTZ =3,098 
- VAN/PTZ = 5,497 
Patients excluded 
N = 6,224 
- Less than 48 hours of treatment = 1,685 
- Combination therapy < 48 hours = 1,508 
- Length of stay < 48 hours = 1,398 
- Baseline CrCl < 30 mL/min = 449 
- AKI within 48 hours of treatment = 446 
- No serum creatinine values = 290 
- AKI occurred prior to treatment = 219 
- AKI occurred > 7 days after treatment 
discontinued = 199 
- Outlier baseline CrCl = 30 
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TABLE 1: Baseline patient characteristics 
Outcome VAN 
(N=3,055) 
PTZ 
(N=3,098) 
VAN/PTZ 
(N=5,497) 
Age (years) [Mean 
(± SD)]  
52.5 (16.9) 53.3 (17.5) 52.0 (16.3) 
Age group (years)  
18-29 333 (10.9%) 379 (12.2%) 594 (10.8%) 
30-49 940 (30.8%) 837 (27.0%) 1736 (31.6%) 
50-64 984 (32.2%) 1034 (33.4%) 1904 (34.6%) 
65-79 630 (20.6%) 632 (20.4%) 1019 (18.5%) 
≥80 168 (5.5%) 216 (7.0%) 244 (4.4%) 
Male gender 1462 (47.9%) 1523 (49.2%) 3257 (59.3%) 
Charlson 
Comorbidity Index 
[Median (IQR)] 
2 (0-4) 2 (0-5) 3 (1-5) 
Baseline creatinine 
clearance (mL/min) 
[Mean (±SD)]* 
100.9 (40.4) 100.1 (42.7) 101.9 (43.6) 
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Outcome VAN 
(N=3,055) 
PTZ 
(N=3,098) 
VAN/PTZ 
(N=5,497) 
CrCl group (mL/min)  
30-59  394 (12.9%) 528 (17.0%) 855 (15.6%) 
60-89  984 (32.2%) 888 (28.7%) 1539 (28.0%) 
≥90  1677 (54.9%) 1682 (54.3%) 3103 (56.4%) 
Transfer from 
outside facility 
646 (21.1%) 867 (28.0%) 1487 (27.1%) 
Admission type 
Elective 904 (29.6%) 398 (12.8%) 644 (11.7%) 
Emergency 1329 (43.5%) 1692 (54.6%) 2956 (53.8%) 
Trauma 102 (3.3%) 137 (4.4%) 524 (9.5%) 
Urgent 720 (23.6%) 871 (28.1%) 1373 (25.0%) 
Hypotension 
exposure 
447 (14.6%) 442 (14.3%) 1560 (28.4%) 
Dehydration 
diagnosis 
98 (3.2%) 225 (7.3%) 312 (5.7%) 
Length of Stay 
(days) [Median 
(IQR)] 
5 (3-9) 5 (3-9) 7 (4-14) 
Total Days of 
Therapy (days) 
[Median (IQR)] 
3 (2-5) 4 (3-6) 5 (4-8) 
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Outcome VAN 
(N=3,055) 
PTZ 
(N=3,098) 
VAN/PTZ 
(N=5,497) 
Length of Stay (days)  
≤7  2084 (68.2%) 2144 (69.2%) 2760 (50.2%) 
8-14  596 (19.5%) 641 (20.7%) 1438 (26.2%) 
15-21  182 (6.0%) 179 (5.8%) 637 (11.6%) 
>21  193 (6.3%) 134 (4.3%) 662 (12.0%) 
Nephrotoxic agent 
exposure 
1970 (64.5%) 1434 (46.3%) 3343 (60.8%) 
Acyclovir 202 (6.6%) 19 (0.6%) 109 (2.0%) 
ACE-inhibitor  595 (19.5%) 545 (17.6%) 1142 (20.8%) 
ARB 159 (5.2%) 133 (4.3%) 167 (3.0%) 
Aminoglycoside 336 (11.0%) 126 (4.1%) 630 (11.5%) 
Amphotericin B 30 (1.0%) 11 (0.4%) 78 (1.4%) 
Cyclosporine* 8 (0.3%) 12 (0.4%) 13 (0.2%) 
Foscarnet* 4 (0.1%) 1 (0.03%) 5 (0.1%) 
Loop diuretic 594 (19.4%) 607 (19.6%) 1828 (33.3%) 
NSAID 874 (28.6%) 309 (10.0%) 752 (13.7%) 
Sulfonamide 19 (0.6%) 18 (0.6%) 95 (1.7%) 
Tacrolimus 34 (1.1%) 75 (2.4%) 108 (2.0%) 
Tenofovir* 27 (0.9%) 18 (0.6%) 29 (0.5%) 
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Footnote for Table 1: 
Reported values are N (%) unless otherwise specified; All values are significantly different 
by standard tests unless denoted by * where p>0.05; SD: standard deviation; IQR: 
interquartile range; CrCl: creatinine clearance; ACE: angiotensin converting enzyme; 
ARB: angiotensin receptor blocker; NSAID: non-steroidal anti-inflammatory drug 
 
Unadjusted Acute Kidney Injury Incidence 
RIFLE-defined AKI occurred in 1,647 (14.1%) across the entire cohort. AKI 
occurred in 21% of VAN/PTZ patients, 8.3% of VAN patients, and 7.8% of PTZ patients 
(p<0.0001). RIFLE-defined Risk, Injury, and Failure occurred more frequently in the 
VAN/PTZ cohort compared to the VAN and PTZ monotherapy groups (Figure 2). There 
were no differences in AKI rates between years studied (r2=0.4732, p=0.2). Patients in the 
VAN/PTZ group experienced AKI on average of 8.0 days after treatment initiation, 
compared to 8.7 and 5.2 days for VAN and PTZ monotherapy groups, respectively. The 
composite of in-hospital mortality and transfer to hospice care was more common in 
VAN/PTZ patients (9.6%) compared to monotherapy groups (VAN 3.9%, PTZ 3.4%), 
most likely due to the increased severity of illness. 
Factors associated with AKI in univariate analyses included treatment with 
VAN/PTZ, days of therapy, baseline creatinine clearance, transfer from outside hospitals, 
CCI, admission type, length of hospitalization, dehydration exposure, and hypotension 
exposure. Exposure to aminoglycosides, amphotericin B, ACE inhibitors, NSAIDs, 
tacrolimus, foscarnet, loop diuretics, sulfonamides, and tenofovir were all associated with 
increased odds of AKI in simple univariate logistic regression. Gender, age, year of 
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treatment, angiotensin II receptor antagonist exposure, and cyclosporine exposure were not 
significantly associated with AKI incidence. 
FIGURE 2: Unadjusted incidence of AKI 
 
Adjusted Acute Kidney Injury Incidence 
After multivariate logistic regression, VAN/PTZ therapy was associated with 
increased odds of AKI compared to VAN and PTZ monotherapies (aORVAN=2.03; 95% 
CIVAN 1.74-2.39; aORPTZ=2.31; 95% CIPTZ 1.97-2.71). No difference in AKI incidence was 
observed between VAN and PTZ groups (aORPTZ compared to VAN=0.88; 95% CI 0.72-1.07). 
Table 2 describes the relationship between AKI and other covariates included in the model. 
Increased odds of AKI were seen with concomitant administration of amphotericin B, 
tacrolimus, loop diuretics, and tenofovir. Patients admitted urgently and emergently were 
at higher risk of AKI, while those admitted via the trauma center were less likely to 
0%
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experience AKI compared to patients who were electively admitted. Increased length of 
stay and duration of therapy were both associated with increased likelihood of AKI, 
independent of treatment group; however, durations of therapy beyond 12 days was not 
associated with increased AKI. Hypotension, as previously defined, and diagnosed 
dehydration both independently increased AKI odds. Aside from those greater than 80 
years old, increasing age was not associated with increased AKI risk. No evidence of 
overfitting was observed with the standardized Hosmer-Lemeshow p-value of 0.33, and 
the model provides good predictive accuracy with a c-statistic of 0.787. 
TABLE 2: Univariate and multivariate association between combination VAN/PTZ 
therapy and AKI odds independent of other baseline covariates 
Covariate 
 
  Unadjusted     Adjusted   
OR 95% CI p OR 95% CI p 
Treatment group             
VAN/PTZ   (ref)     (ref)   
PTZ  0.34 0.29 - 0.39 <0.001 0.49 0.42 - 0.58 <0.001 
VAN  0.32 0.27 - 0.37 <0.001 0.43 0.37 - 0.51 <0.001 
Gender          
Female   (ref)      
Male 0.99 0.89 - 1.10 0.896    
Age (years)             
18-29   (ref)     (ref)   
30-49 1.09 0.91 - 1.32 0.361 0.98 0.80 - 1.21 0.862 
50-64 1.23 1.02 - 1.48 0.031 1.04 0.84 - 1.30 0.697 
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Covariate 
 
  Unadjusted     Adjusted   
OR 95% CI p OR 95% CI p 
Age (years)       
65-79 1.11 0.91 - 1.36 0.316 1.17 0.92 - 1.50 0.201 
≥ 80 1.12 0.84 - 1.47 0.427 1.8 1.28 - 2.52 0.001 
CCI (per point) 1.07 1.06 - 1.09 <0.001 1.05 1.03 - 1.07 <0.001 
Baseline CrCl 
(mL/min) 
      
      
30-59   (ref)     (ref)   
60-89 1.02 0.85 - 1.23 0.816 1.4 1.14 - 1.72 0.002 
≥ 90 1.7 1.45 - 2.01 <0.001 3.36 2.75 - 4.14 <0.001 
Admission type             
Elective   (ref)    (ref)   
Emergency 1.19 1.02 - 1.39 0.033 1.21 1.01 - 1.45 0.038 
Trauma 1.03 0.79 - 1.33 0.82 0.49 0.37 - 0.65 <0.001 
Urgent 1.63 1.38 - 1.94 <0.001 1.39 1.14 - 1.71 0.001 
Transfer from 
outside facility 
1.56 1.39 - 1.74 <0.001 1.14 0.99 - 1.32 0.06 
Hypotension 
exposure 
2.81 2.52 - 3.15 <0.001 1.59 1.39 - 1.82 <0.001 
Dehydration 
exposure 
1.29 1.04 - 1.59 0.018 1.33 1.05 - 1.68 0.017 
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Covariate 
 
  Unadjusted     Adjusted   
OR 95% CI p OR 95% CI p 
Nephrotoxic drug 
exposures 
            
Acyclovir 1.22 0.90 - 1.63 0.182 1.05 0.75 - 1.44 0.791 
Aminoglycoside 1.89 1.62 - 2.20 <0.001 1.15 0.96 - 1.38 0.119 
Amphotericin B 4.35 2.99 - 6.27 <0.001 2.22 1.45 - 3.37 <0.001 
ACE inhibitor 1.34 1.18 - 1.51 <0.001 1.15 1.00 - 1.32 0.052 
ARB 0.87 0.65 - 1.15 0.347 1.18 0.86 - 1.60 0.301 
Cyclosporine 1.35 0.50 - 3.06 0.506 0.78 0.24 - 2.10 0.642 
Foscarnet 6.09 1.69 - 21.92 0.004 1.98 0.41 - 9.46 0.387 
Loop diuretic 3.51 3.15 - 3.91 <0.001 2.04 1.79 - 2.33 <0.001 
NSAID 0.82 0.71 - 0.95 0.009 0.98 0.83 - 1.16 0.848 
Sulfonamide 1.8 1.18 - 2.68 0.005 1.38 0.86 - 2.15 0.163 
Tacrolimus 2.66 1.97 - 3.56 <0.001 2.08 1.45 - 2.96 <0.001 
Tenofovir 1.96 1.12 - 3.28 0.013 1.85 1.00 - 3.29 0.043 
Year of admission             
2010   (ref)        
2011 0.85 0.69 - 1.05 0.127      
2012 0.95 0.78 - 1.18 0.657      
2013 0.87 0.70 - 1.07 0.176      
2014 0.84 0.67 - 1.05 0.121       
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Covariate 
 
  Unadjusted     Adjusted   
OR 95% CI p OR 95% CI p 
Duration of therapy 
(days) 
      
      
2-3   (ref)     (ref)   
4-5 1.81 1.55 - 2.13 <0.001 1.32 1.12 - 1.56 0.001 
6-7 3.23 2.74 - 3.81 <0.001 1.79 1.49 - 2.15 <0.001 
8-9 5.09 4.22 - 6.13 <0.001 2 1.61 - 2.48 <0.001 
10-11 5.94 4.71 - 7.46 <0.001 1.95 1.50 - 2.54 <0.001 
12-13 5.25 3.84 - 7.12 <0.001 1.41 0.99 - 1.98 0.054 
≥ 14 5.31 4.19 - 6.72 <0.001 1.27 0.95 - 1.70 0.107 
Length of stay 
(days) 
     
     
≤ 7   (ref)     (ref)   
8-14 3.35 2.94 - 3.81 <0.001 2.03 1.74 - 2.36 <0.001 
15-21 4.48 3.79 - 5.29 <0.001 2.28 1.86 - 2.81 <0.001 
>21 5.88 5.01 - 6.91 <0.001 2.72 2.18 - 3.39 <0.001 
 
 
Footnote for Table 2: 
PTZ: piperacillin-tazobactam; VAN: vancomycin; VAN/PTZ: vancomycin plus 
piperacillin-tazobactam; CrCl: creatinine clearance; CCI: Charlson Comorbidity Index; 
ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; NSAID: non-
steroidal anti-inflammatory drug  
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Chapter Four: Conclusions 
Summary of Findings 
 Acute kidney injury secondary to vancomycin therapy is a well characterized 
adverse effect, while AKI incidence secondary to piperacillin-tazobactam is less 
understood. Additionally, there appears to be an increased effect when these agents are 
used in combination. To date, this is the largest review of AKI in patients receiving 
vancomycin, piperacillin-tazobactam, or the combination of both agents.  
 There has been a recent surge in evidence suggesting increased nephrotoxicity in 
patients treated with the combination of vancomycin and anti-pseudomonal beta-lactams. 
The mechanism for the apparent increase in nephrotoxicity with the combination is not 
well-understood and needs further study in both animal models and humans.  
 Acute kidney injury rates related to vancomycin vary widely, with recent studies in 
critically ill and internal medicine patients estimating rates of 21% and 13.6%, 
respectively.[2,3] In our vancomycin monotherapy cohort, which includes critically ill 
patients, the AKI rate was 8.3%, with 2.3% of patients experiencing a greater than 50% 
decrease in creatinine clearance. Piperacillin-tazobactam-related AKI rates are not well-
characterized; however, a small retrospective analysis estimated that 11.1% of piperacillin-
tazobactam patients experienced acute renal failure (defined as either increase in serum 
creatinine ≥ 0.5 mg/dL or 50% increase from baseline).[13] In the present study, we found 
the piperacillin-tazobactam-related AKI rate to be 7.8%, which may be due to a more 
stringent definition of AKI. Additionally, Hellwig et al [13], found that piperacillin-
tazobactam monotherapy was associated with higher AKI rates compared to vancomycin 
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monotherapy (11.1% vs. 4.9%; p=0.014). This was not replicated in our study, with 
vancomycin and piperacillin-tazobactam monotherapy having similar AKI rates (8.3% and 
7.8%, respectively) and an adjusted odds ratio for AKI between piperacillin-tazobactam 
and vancomycin of 0.88 (95% CI 0.72-1.07). The estimated AKI incidence in the 
combination therapy group of 21% at our institution is consistent with prior literature which 
ranges from 16.3 to 34.8%.[4-8, 13]  
Limitations  
 This study is not without limitations. As with all retrospective studies, it is difficult 
to determine a causal link between vancomycin and piperacillin-tazobactam combination 
therapy and increased AKI incidence due to confounding. We employed a rigorous study 
design that controlled for major confounders of AKI, such as concomitant nephrotoxic 
exposure, hypotension, and previous renal disease. Nephrotoxic potential of agents was 
assumed to be equal, which is not necessarily true. Additionally, the binary representation 
of nephrotoxic exposure does not describe the amount of the agent received; as such, our 
estimations of AKI odds may be artificially elevated. Approximately one quarter of the 
patients in this study were transferred from an outside hospital, for which no data regarding 
initial treatment is available. This may lead to exposure misclassification; however, we 
attempted to control for this factor in the regression model and found that, after controlling 
for other covariates, hospital transfer was not associated with odds of AKI. Finally, data 
was collected retrospectively from the electronic medical record and is subject to 
inaccuracies documented in the chart; however, any bias introduced should be 
nondifferential. 
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Application to Clinical Practice 
 In our large retrospective study of combination empiric therapy with vancomycin 
and piperacillin-tazobactam, we found that combination therapy was associated with over 
double the odds of AKI occurring compared to either monotherapy with vancomycin or 
piperacillin-tazobactam. Increasing duration of therapy was also associated with increases 
in AKI. These findings demonstrate the need for judicious use of combination therapy and 
strengthen the need for antimicrobial de-escalation when appropriate in order to avoid 
deleterious effects.  
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Appendix A: R codes 
#### Acute Kidney injury in Vanc mono vs. PTZ mono vs. PTZ+VAN 
meds<-read.csv('../Desktop/AKI data files/New_meds.csv', 
colClasses='character') 
##Cleaning up the medication dataset for better analysis. 
meds$drug<-meds$Name                                ##Using a separate 
dataset so nothing is changed in the origninal unintentionally 
meds$drug<-sub('Inj\\.','',meds$drug) 
meds$drug<-sub('\\(Drip\\)','',meds$drug) 
meds$drug<-sub('\\(PEDIATRIC\\)','',meds$drug) 
meds$drug<-sub('\\(IntraMuscular\\)','',meds$drug) 
meds$drug<-sub('-','',meds$drug) 
meds$drug<-sub('Inj','',meds$drug) 
library(stringr)                                      ##Load the stringr 
package for access to the str_trim which eliminates whitespace 
meds$drug<-str_trim(meds$drug)                      ##generated in the 
steps above 
meds$drug<-sub('zzz','',meds$drug) 
meds$drug<-sub('Piperacillin / Tazobactam','PTZ',meds$drug) 
library(dplyr) 
meds2<-select(meds, Encounter.ID, MRN, drug) 
meds2<-unique(meds2) 
library(data.table) 
meds2<-as.data.table(meds2) 
meds3<-dcast.data.table(data = meds2, Encounter.ID+MRN~drug) 
 
 
for(i in 1:nrow(meds3)){ 
  if(!is.na(meds3$Cefepime[i]) & is.na(meds3$PTZ[i]) & 
is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='CM' 
  } 
  if(is.na(meds3$Cefepime[i]) & !is.na(meds3$PTZ[i]) & 
is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='PM' 
  } 
  if(is.na(meds3$Cefepime[i]) & is.na(meds3$PTZ[i]) & 
!is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='VM' 
  } 
  if(is.na(meds3$Cefepime[i]) & !is.na(meds3$PTZ[i]) & 
!is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='PV' 
  } 
  if(!is.na(meds3$Cefepime[i]) & is.na(meds3$PTZ[i]) & 
!is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='CV' 
  } 
  if(!is.na(meds3$Cefepime[i]) & !is.na(meds3$PTZ[i]) & 
is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='CP' 
  } 
  if(!is.na(meds3$Cefepime[i]) & !is.na(meds3$PTZ[i]) & 
!is.na(meds3$Vancomycin[i])){ 
    meds3$group[i]='CVP' 
  } 
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} 
 
demo<-read.csv('../Desktop/AKI data files/demo.csv', 
colClasses='character')    ##Imports RAW files 
demo<-demo[demo$ENCNTR_ID %in% meds3$Encounter.ID,] 
demo$EID<-demo$ENCNTR_ID 
demo$ENCNTR_ID<-NULL 
meds3$EID<-meds3$Encounter.ID 
meds4<-select(meds3, EID, group) 
demo2<-merge(demo, meds4, by='EID') 
dat<-demo2[demo2$group %in% c('PM','PV','VM'),] 
dat$AGE<-as.numeric(dat$AGE) 
dat<-dat[dat$AGE>=18,] 
dat$LENGTH_OF_STAY_NUM<-as.numeric(dat$LENGTH_OF_STAY_NUM) 
dat<-dat[dat$LENGTH_OF_STAY_NUM>=2,] 
meds<-meds[meds$Encounter.ID %in% demo2$EID,] 
 
labs<-read.csv('../Desktop/AKI data files/New Labs.csv', 
colClasses='character') 
labs<-labs[labs$ENCNTR_ID %in% dat$EID,] 
scr<-labs[grepl('creatinine level', labs$ITEM_NAME, ignore.case = T),] 
scr$date<-as.POSIXct(scr$ENTRD_DT_TM, format="%m/%d/%Y %I:%M:%S %p") 
scr$VAL_NUM<-as.numeric(scr$VAL_NUM) 
scr<-scr[!is.na(scr$VAL_NUM),] 
scr$EID<-scr$ENCNTR_ID 
 
dat<-dat[dat$EID %in% scr$EID,] 
 
for(i in 1:nrow(dat)){ 
  x<-scr[scr$EID == dat$EID[i],] 
  dat$baseline_scr_date[i]<-as.character(min(x$date)) 
  dat$baseline_scr[i]<-x$VAL_NUM[x$date==min(x$date)] 
} 
 
for(i in 1:nrow(dat)){ 
  x<-scr[scr$EID==dat$EID[i],] 
  dat$max_scr_date[i]<-as.character(x$date[x$VAL_NUM==max(x$VAL_NUM, 
na.rm=T)]) 
  dat$max_scr[i]<-max(x$VAL_NUM, na.rm=T) 
} 
 
class(meds$Performed.Date.Time) 
meds$date<-sapply(strsplit(x = meds$Performed.Date.Time, split = ' 
'),'[',1) 
van<-meds[grepl('vancomycin', ignore.case = T, meds$drug),] 
ptz<-meds[grepl('PTZ', meds$drug),] 
 
for( i in 1:nrow(dat)){ 
  medx<-meds[meds$Encounter.ID == dat$EID[i],] 
  dat$Total_DOT[i]<-length(unique(medx$date)) 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$group[i]=='PV'){ 
    vanx<-van[van$Encounter.ID == dat$EID[i],] 
    ptzx<-ptz[ptz$Encounter.ID == dat$EID[i],] 
    dat$Van_DOT[i]<-length(unique(vanx$date)) 
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    dat$PTZ_DOT[i]<-length(unique(ptzx$date)) 
  } 
  if(dat$group[i]=='PM'){ 
    dat$Van_DOT[i]<-NA 
    dat$PTZ_DOT[i]<-dat$Total_DOT[i] 
  } 
  if(dat$group[i]=='VM'){ 
    dat$PTZ_DOT[i]<-NA 
    dat$Van_DOT[i]<-dat$Total_DOT[i] 
  } 
} 
 
medstest<-meds[meds$Encounter.ID %in% dat$EID,] 
dot(medstest) 
library(plyr) 
dot2<-ldply(DOT_list) 
dot3<-select(dot2, V1,V5) 
dot3$EID<-dot3$V1 
dot3$Combo_DOT<-dot3$V5 
dot3$V1<-NULL 
dot3$V5<-NULL 
dat<-merge(dat, dot3, by='EID') 
 
dat<-dat[dat$Total_DOT>=2,] 
 
 
for(i in 1:nrow(dat)){ 
  if(dat$GENDER[i]=='UNKNOWN'){ 
    dat$GENDER[i]<-'MALE' 
  } 
} 
dat$baseline_scr<-as.numeric(dat$baseline_scr) 
dat$max_scr<-as.numeric(dat$max_scr) 
 
for(i in 1:nrow(dat)){ 
  dat$baseline_crcl[i]<-(140-dat$AGE[i])/dat$baseline_scr[i] 
  dat$min_crcl[i]<-(140-dat$AGE[i])/dat$max_scr[i] 
  if(dat$GENDER[i]=='FEMALE'){ 
    dat$baseline_crcl[i]<-dat$baseline_crcl[i]*0.85 
    dat$min_crcl[i]<-dat$min_crcl[i]*0.85 
  } 
} 
 
dat$percent_change<-(dat$min_crcl/dat$baseline_crcl-1)*100         
for(i in 1:length(dat$EID)){                                      ##assign 
RIFLE labels to appropriate degrees of renal impairment 
  if (dat$percent_change[i]>=0){                                  ##if 
percent_change is >=0, the max SCr is equal to baseline, suggesting GFR 
improvement 
    dat$RIFLE[i]<-"No injury" 
  } 
  else { 
    if (abs(dat$percent_change[i])<25){ 
      dat$RIFLE[i]<-'No injury' 
    } 
    if (abs(dat$percent_change[i])>=25 & abs(dat$percent_change[i])<50){ 
      dat$RIFLE[i] <-'RISK' 
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    } 
    if (abs(dat$percent_change[i])>=50 & abs(dat$percent_change[i])<75){ 
      dat$RIFLE[i] <-'INJURY' 
    } 
    if (abs(dat$percent_change[i])>=75){ 
      dat$RIFLE[i] <- 'Failure' 
    } 
  } 
} 
 
for(i in 1:length(dat$EID)){                                    ##Assigns 
binary outcome for AKI (Risk, Injury, Failure) vs No AKI 
  if(dat$RIFLE[i] =='No injury'){                               ##Can 
convert to a 0/1 answer for modeling.  
    dat$AKI[i]<-"No AKI" 
  } 
  else{ 
    dat$AKI[i]<-'AKI' 
  } 
} 
 
dat$van_start<-NA 
dat$ptz_start<-NA 
ptz$date<-as.Date(ptz$date, format='%m/%d/%Y') 
van$date<-as.Date(van$date, format='%m/%d/%Y') 
 
 
for(i in 1:nrow(dat)){ 
  if(dat$group[i]=='PM'){ 
    #x<-van[van$Encounter.ID==dat$EID[i],] 
    #x<-x[!is.na(x$date),] 
    #dat$van_start[i]<-as.character(min(x$date)) 
    y<-ptz[ptz$Encounter.ID==dat$EID[i],] 
    y<-y[!is.na(y$date),] 
    dat$ptz_start[i]<-as.character(min(y$date)) 
    dat$van_start[i]<-NA 
  } 
  if(dat$group[i]=='VM'){ 
    x<-van[van$Encounter.ID==dat$EID[i],] 
    x<-x[!is.na(x$date),] 
    dat$van_start[i]<-as.character(min(x$date)) 
    dat$ptz_start[i]<-NA 
    #y<-ptz[ptz$Encounter.ID==dat$EID[i],] 
    #y<-y[!is.na(y$date),] 
    #dat$ptz_start[i]<-as.character(min(y$date)) 
  } 
  if(dat$group[i]=='PV'){ 
    x<-van[van$Encounter.ID==dat$EID[i],] 
    x<-x[!is.na(x$date),] 
    dat$van_start[i]<-as.character(min(x$date)) 
    y<-ptz[ptz$Encounter.ID==dat$EID[i],] 
    y<-y[!is.na(y$date),] 
    dat$ptz_start[i]<-as.character(min(y$date)) 
  } 
} 
 
dat$ptz_start<-as.Date(dat$ptz_start) 
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dat$van_start<-as.Date(dat$van_start) 
 
for(i in 1:nrow(dat)){ 
  dat$tx_index[i]<-as.character(min(dat$van_start[i], dat$ptz_start[i], 
na.rm = T)) 
} 
dat$tx_index<-as.Date(dat$tx_index) 
 
for(i in 1:nrow(dat)){ 
  if(dat$group[i]=='PM' | dat$group[i]=='VM'){ 
    dat$Combo_DOT[i]<-NA 
  } 
} 
 
dat<-dat[dat$Combo_DOT>=2 | is.na(dat$Combo_DOT),] 
crclcut<-mean(dat$baseline_crcl)+4*sd(dat$baseline_crcl) 
dat<-dat[dat$baseline_crcl<=crclcut,] 
dat<-dat[dat$baseline_crcl>=30,] 
 
dat$max_scr_date2<-sapply(strsplit(dat$max_scr_date, ' '),'[',1) 
dat$max_scr_date2<-as.Date(dat$max_scr_date2) 
 
 
for(i in 1:nrow(dat)){ 
  if(dat$max_scr_date2[i] < dat$tx_index[i]){ 
    dat$aki_before_tx[i]<-'Y' 
  } 
  else{ 
    dat$aki_before_tx[i]<-'N' 
  } 
} 
 
dat<-dat[!(dat$aki_before_tx=='Y' & dat$AKI=='AKI'),] 
 
for(i in 1:nrow(dat)){ 
  if(dat$AKI[i]=='No AKI'){ 
    dat$time_to_aki[i]<-NA 
  } 
  else{ 
    dat$time_to_aki[i]<-as.numeric(dat$max_scr_date2[i]-
dat$tx_index[i]) 
  } 
} 
 
dat_b<-dat 
dat<-dat[dat$time_to_aki>=2 | is.na(dat$time_to_aki),] 
 
 
dat$van_end<-NA 
dat$ptz_end<-NA 
 
for(i in 1:nrow(dat)){ 
  if(dat$group[i]=='VM'){ 
    x<-van[van$Encounter.ID==dat$EID[i],] 
    x<-x[!is.na(x$date),] 
    dat$van_end[i]<-as.character(max(x$date)) 
    dat$ptz_end[i]<-NA 
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  } 
  if(dat$group[i]=='PM'){ 
    dat$van_end[i]<-NA 
    y<-ptz[ptz$Encounter.ID==dat$EID[i],] 
    y<-y[!is.na(y$date),] 
    dat$ptz_end[i]<-as.character(max(y$date)) 
  } 
  if(dat$group[i]=='PV'){ 
    x<-van[van$Encounter.ID==dat$EID[i],] 
    x<-x[!is.na(x$date),] 
    dat$van_end[i]<-as.character(max(x$date)) 
    y<-ptz[ptz$Encounter.ID==dat$EID[i],] 
    y<-y[!is.na(y$date),] 
    dat$ptz_end[i]<-as.character(max(y$date)) 
  } 
} 
 
dat$van_end<-as.Date(dat$van_end) 
dat$ptz_end<-as.Date(dat$ptz_end) 
for(i in 1:nrow(dat)){ 
  dat$tx_end[i]<-as.character(max(dat$van_end[i], dat$ptz_end[i], na.rm 
= T)) 
} 
dat$tx_end<-as.Date(dat$tx_end) 
for( i in 1:nrow(dat)){ 
  if(as.numeric(dat$tx_end[i] - dat$max_scr_date2[i])> 7){ 
    dat$aki_out_range[i]<-'Y' 
  } 
  else{ 
    dat$aki_out_range[i]<-'N' 
  } 
} 
 
dat<-dat[!(dat$aki_out_range=='Y' & dat$AKI=='AKI'),] 
 
 
for(i in 1:length(dat$EID)){                                                   
##gives a single Y/N variable for occurence of hypotension 
  
ifelse(dat$MEAN_ARTERIAL_UNDER_60_FLG[i]=='Y'|dat$HYPOTENSION_FLG[i]=='
Y'|   ##this excludes SBP < 100 mmHg flag as this really isn't defensible 
           dat$VASOPRESSORS_FLG[i]=='Y'|dat$INOTROPES_FLG[i]=='Y', 
         dat$hypotension[i]<-'Y',dat$hypotension[i]<-'N') 
} 
 
for(i in 1:length(dat$EID)){                                                 ##Y/N 
for nephrotoxic drug exposure. Does not give a count. 
  ifelse(dat$ACYCLOVIR_FLG[i]=='Y'| 
dat$AMINOGLYCOSIDES_FLG[i]=='Y'|dat$AMPHOTERICIN_B_FLG[i]=='Y'| 
           dat$ANGIOTENSIN_FLG[i]=='Y'| 
dat$ANGIOTENSION_FLG[i]=='Y'|dat$COLISTIN_FLG[i]=='Y' |  
           dat$CYCLOSPORINE_FLG[i]=='Y'| dat$FOSCARNET_FLG[i]=='Y'| 
dat$LOOP_DIURETICS_FLG[i]=='Y'| 
           dat$NON_STEROIDAL_ANTI_FLG[i]=='Y'| 
dat$SULFONAMIDES_FLG[i]=='Y'| dat$TACROLIMUS_FLG[i]=='Y'| 
           dat$TENOFOVIR_FLG[i]=='Y',dat$nephrotoxic_drug[i]<-
"Y",dat$nephrotoxic_drug[i]<-"N") 
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} 
 
labs<-labs[labs$ENCNTR_ID %in% dat$EID,] 
meds<-meds[meds$Encounter.ID %in% dat$EID,] 
ptz<-meds[meds$drug=='PTZ',] 
van<-meds[meds$drug=='Vancomycin',] 
 
dat$year<-sapply(strsplit(as.character(dat$tx_index), '-',),'[',1) 
 
van$Dose<-as.numeric(van$Dose) 
for(i in 1:nrow(van)){ 
  if(van$UOM[i]=='gram'){ 
    van$Dose[i]<-van$Dose[i]*1000 
    van$UOM[i]<-'MG' 
  } 
} 
 
for(i in 1:nrow(van)){ 
  if(van$Dose[i]==1){ 
    van$Dose[i]<-1000 
  } 
  if(van$Dose[i]==100){ 
    van$Dose[i]<-1500 
  } 
} 
 
van$date<-sapply(strsplit(van$Performed.Date.Time, ' '),'[',1) 
van$date<-as.Date(van$date, format='%m/%d/%Y') 
 
for(i in 1:nrow(dat)){ 
  if(dat$group[i]=='PM'){ 
    dat$avg_daily_van_dose[i]<-NA 
  } 
  if(dat$group[i] %in% c('PV','VM')){ 
    x<-van[van$Encounter.ID==dat$EID[i],] 
    dat$avg_daily_van_dose[i]<-mean(by(x$Dose, x$date, sum)) 
  } 
} 
 
labs<-labs[labs$ENCNTR_ID %in% dat$EID,] 
vtr<-labs[grepl('trough', labs$ITEM_NAME, ignore.case = T),] 
vtr$VAL_NUM<-as.numeric(vtr$VAL_NUM) 
vtr$date<-sapply(strsplit(vtr$ENTRD_DT_TM, ' '), '[',1) 
vtr$date<-as.Date(vtr$date, format='%m/%d/%Y') 
vtr<-vtr[!is.na(vtr$VAL_NUM),] 
 
for(i in 1:nrow(dat)){ 
  if(!(dat$EID[i] %in% vtr$ENCNTR_ID)){ 
    dat$first_van_tr[i]<-NA 
    dat$first_van_tr_date[i]<-NA 
    dat$max_van_tr[i]<-NA 
    dat$max_van_tr_date[i]<-NA     
  } 
  if(dat$EID[i] %in% vtr$ENCNTR_ID){ 
    x<-vtr[vtr$ENCNTR_ID==dat$EID[i],] 
    dat$first_van_tr[i]<-x$VAL_NUM[x$date==min(x$date)] 
    dat$first_van_tr_date[i]<-as.character(min(x$date)) 
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    dat$max_van_tr[i]<-max(x$VAL_NUM) 
    dat$max_van_tr_date[i]<-
as.character(x$date[x$VAL_NUM==max(x$VAL_NUM)]) 
  } 
} 
dat$max_van_tr<-as.numeric(dat$max_van_tr) 
dat$first_van_tr<-as.numeric(dat$first_van_tr) 
 
for(i in 1:nrow(dat)){ 
  if(!is.na(dat$first_van_tr[i])){ 
    if(dat$first_van_tr[i]<10){ 
      dat$first_van_tr_class[i]<-'subtherapeutic' 
    } 
    if(dat$first_van_tr[i]<15 & dat$first_van_tr[i]>=10){ 
      dat$first_van_tr_class[i]<-'therapeutic_low' 
    } 
    if(dat$first_van_tr[i]<=20 & dat$first_van_tr[i]>=15){ 
      dat$first_van_tr_class[i]<-'therapeutic_high' 
    } 
    if(dat$first_van_tr[i]>20){ 
      dat$first_van_tr_class[i]<-'supratherapeutic' 
    } 
  } 
  if(!is.na(dat$max_van_tr[i])){ 
    if(dat$max_van_tr[i]<10){ 
      dat$max_van_tr_class[i]<-'subtherapeutic' 
    } 
    if(dat$max_van_tr[i]<15 & dat$max_van_tr[i]>=10){ 
      dat$max_van_tr_class[i]<-'therapeutic_low' 
    } 
    if(dat$max_van_tr[i]<=20 & dat$max_van_tr[i]>=15){ 
      dat$max_van_tr_class[i]<-'therapeutic_high' 
    } 
    if(dat$max_van_tr[i]>20){ 
      dat$max_van_tr_class[i]<-'supratherapeutic' 
    } 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(is.na(dat$max_van_tr[i])){ 
    dat$max_van_tr_class[i]<-NA 
    dat$first_van_tr_class[i]<-NA 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$baseline_crcl[i]>=90){ 
    dat$baseline_crcl_group[i]<-'>=90' 
    dat$baseline_crcl_group_num[i]<-'1' 
  } 
  if(dat$baseline_crcl[i]<90 & dat$baseline_crcl[i]>=60){ 
    dat$baseline_crcl_group[i]<-'>=60 to <90' 
    dat$baseline_crcl_group_num[i]<-'2' 
  } 
  if(dat$baseline_crcl[i]<60 & dat$baseline_crcl[i]>=30){ 
    dat$baseline_crcl_group[i]<-'>=30 to <60' 
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    dat$baseline_crcl_group_num[i]<-'3' 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$AKI[i] =='AKI'){ 
    dat$aki_num[i]<-1 
  } 
  else{ 
    dat$aki_num[i]<-0 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(grepl('TRANS', dat$ADMT_SRC_CD_DES[i])){ 
    dat$transfer[i]<-1 
  } 
  else{ 
    dat$transfer[i]<-0 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(grepl('HOSPICE', dat$DISCHRG_DES[i])| grepl('DEATH', 
dat$DISCHRG_DES[i])){ 
    dat$mortality[i]<-1 
  } 
  else{ 
    dat$mortality[i]<-0 
  } 
} 
dat$TOTAL_CHARLSON_SCORE<-as.numeric(dat$TOTAL_CHARLSON_SCORE) 
 
for(i in 1:nrow(dat)){ 
  if(dat$AGE[i]>=65){ 
    dat$age_65[i]<-'Y' 
  } 
  else{ 
    dat$age_65[i]<-'N' 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$AGE[i]<30){ 
    dat$age_group[i]<-'<30' 
  } 
  if(dat$AGE[i]>=30 & dat$AGE[i]<50){ 
    dat$age_group[i]<-'30 to <50' 
  } 
  if(dat$AGE[i]>=50 & dat$AGE[i]<65){ 
    dat$age_group[i]<-'50 to <65' 
  } 
  if(dat$AGE[i]>=65 & dat$AGE[i]<80){ 
    dat$age_group[i]<-'65 to <80' 
  } 
  if(dat$AGE[i]>=80){ 
    dat$age_group[i]<-'>=80' 
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  } 
} 
for(i in 1:nrow(dat)){ 
  if(dat$LENGTH_OF_STAY_NUM[i]>7){ 
    dat$los_7[i]<-'Y' 
  } 
  else{ 
    dat$los_7[i]<-'N' 
  } 
} 
dat$los_weeks<-dat$LENGTH_OF_STAY_NUM/7 
 
for(i in 1:nrow(dat)){ 
  if(dat$LENGTH_OF_STAY_NUM[i]<=7){ 
    dat$los_group[i]<-'<=7' 
  } 
  if(dat$LENGTH_OF_STAY_NUM[i]>7 & dat$LENGTH_OF_STAY_NUM[i]<=14){ 
    dat$los_group[i]<-'8-14' 
  } 
  if(dat$LENGTH_OF_STAY_NUM[i]>14 & dat$LENGTH_OF_STAY_NUM[i]<=21){ 
    dat$los_group[i]<-'15-21' 
  } 
  if(dat$LENGTH_OF_STAY_NUM[i]>21){ 
    dat$los_group[i]<-'>21' 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$ANGIOTENSIN_FLG[i] =='Y' | dat$ANGIOTENSION_FLG[i]=='Y'){ 
    dat$ace.arb[i]<-'Y' 
  } 
  else{ 
    dat$ace.arb[i]<-'N' 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$TACROLIMUS_FLG[i] =='Y' | dat$CYCLOSPORINE_FLG[i]=='Y'){ 
    dat$tac.cyc[i]<-'Y' 
  } 
  else{ 
    dat$tac.cyc[i]<-'N' 
  } 
} 
 
#begin simple models 
x<-'binomial' 
age<-glm(aki_num~AGE, family='binomial') #AGE as continuous variable 
age65<-glm(aki_num~age_65, family='binomial', data=dat) # age as binary 
>=65 variable 
agegroup<-glm(aki_num~age_group, family='binomial', data=dat) 
gender<-glm(aki_num~GENDER, family='binomial', data=dat) 
cci<-glm(aki_num~TOTAL_CHARLSON_SCORE, family = 'binomial', data=dat) 
adsrc<-glm(aki_num~ADMT_SRC_CD_DES, family='binomial', data=dat) #ugly 
regression use adtype 
adtype<-glm(aki_num~ADMT_TYP_CD_DES, family=x, data=dat) 
los<-glm(aki_num~LENGTH_OF_STAY_NUM, family=x, data=dat) 
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los7<-glm(aki_num~los_7, family=x, data=dat) 
losw<-glm(aki_num~los_weeks, family=x, data=dat) 
losg<-glm(aki_num~los_group, family=x, data=dat) 
map<-glm(aki_num~MEAN_ARTERIAL_UNDER_60_FLG, family=x, data=dat) 
dehy<-glm(aki_num~DEHYDRATION_FLG, family=x, data=dat) 
hypof<-glm(aki_num~HYPOTENSION_FLG, family=x, data=dat) 
acy<-glm(aki_num~ACYCLOVIR_FLG, family=x, data=dat) 
ag<-glm(aki_num~AMINOGLYCOSIDES_FLG, family=x, data=dat) 
ab<-glm(aki_num~AMPHOTERICIN_B_FLG, family=x, data=dat) 
ace<-glm(aki_num~ANGIOTENSIN_FLG,family=x, data=dat) 
arb<-glm(aki_num~ANGIOTENSION_FLG, family=x, data=dat) 
acearb<-glm(aki_num~ace.arb, family=x, data=dat) 
cyc<-glm(aki_num~CYCLOSPORINE_FLG, family=x, data=dat) 
tac<-glm(aki_num~TACROLIMUS_FLG, family=x, data=dat) 
taccyc<-glm(aki_num~tac.cyc, family=x, data=dat) 
fos<-glm(aki_num~FOSCARNET_FLG, family=x, data=dat) 
loop<-glm(aki_num~LOOP_DIURETICS_FLG, family=x, data=dat) 
nsaids<-glm(aki_num~NON_STEROIDAL_ANTI_FLG, family=x, data=dat) 
sulf<-glm(aki_num~SULFONAMIDES_FLG, family=x, data=dat) 
ten<-glm(aki_num~TENOFOVIR_FLG, family=x, data=dat) 
vas<-glm(aki_num~VASOPRESSORS_FLG, family=x, data=dat) 
ino<-glm(aki_num~INOTROPES_FLG, family=x, data=dat) 
txgroup<-glm(aki_num~group, family=x, data=dat) 
tdot<-glm(aki_num~Total_DOT, family=x, data=dat) 
vdot<-glm(aki_num~Van_DOT, x, dat) 
pdot<-glm(aki_num~PTZ_DOT, x, dat) 
crcl<-glm(aki_num~baseline_crcl, x, dat) 
crclg<-glm(aki_num~factor(baseline_crcl_group),x,dat) 
hypoc<-glm(aki_num~hypotension, x, dat) 
neph<-glm(aki_num~nephrotoxic_drug, x, dat) 
yr<-glm(aki_num~factor(year), x, dat) 
vd<-glm(aki_num~avg_daily_van_dose, x, dat) 
dat$avd_grams<-dat$avg_daily_van_dose/1000 
vdg<-glm(aki_num~avd_grams, x, dat) 
trans<-glm(aki_num~transfer, x, dat) 
 
dat$group<-relevel(dat$group, ref = 'PV') 
 
model1lrm<-
lrm(aki_num~group+age_65+TOTAL_CHARLSON_SCORE+transfer+DEHYDRATION_FLG+
ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMPHOTERICIN_B_FLG+ANGIOTENSIN_FLG 
               + 
LOOP_DIURETICS_FLG+TACROLIMUS_FLG+Total_DOT+baseline_crcl_group+hypoten
sion, data=dat) 
model1glm<-
glm(aki_num~group+age_65+TOTAL_CHARLSON_SCORE+transfer+DEHYDRATION_FLG+
ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMPHOTERICIN_B_FLG+ANGIOTENSIN_FLG 
               + 
LOOP_DIURETICS_FLG+TACROLIMUS_FLG+Total_DOT+baseline_crcl_group+hypoten
sion, data=dat, x) 
 
compmodelglm<-glm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                    
year+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FL
G+ AMPHOTERICIN_B_FLG+ 
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ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                    TENOFOVIR_FLG+Total_DOT+nephrotoxic_drug, x, dat) 
compmodellrm<-lrm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                    
year+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FL
G+ AMPHOTERICIN_B_FLG+ 
                    
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                    TENOFOVIR_FLG+Total_DOT+nephrotoxic_drug, dat) 
 
compsteplrm<-lrm(aki_num ~ group + factor(age_group) + 
TOTAL_CHARLSON_SCORE +  
                   factor(baseline_crcl_group) + transfer + hypotension 
+ GENDER +  
                   year + factor(los_group) + DEHYDRATION_FLG + 
AMPHOTERICIN_B_FLG +  
                   tac.cyc + LOOP_DIURETICS_FLG + NON_STEROIDAL_ANTI_FLG 
+ TENOFOVIR_FLG +  
                   Total_DOT + nephrotoxic_drug, dat) 
 
finmodel1glm<-glm(aki_num ~ group + factor(age_group) + 
TOTAL_CHARLSON_SCORE +  
                    factor(baseline_crcl_group) + transfer + hypotension 
+ GENDER +  
                    factor(year) + factor(los_group) + DEHYDRATION_FLG + 
AMPHOTERICIN_B_FLG +  
                    tac.cyc + LOOP_DIURETICS_FLG + 
NON_STEROIDAL_ANTI_FLG + TENOFOVIR_FLG +  
                    Total_DOT,x, dat) 
finmodel2lglm<-glm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                     
factor(year)+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCO
SIDES_FLG+ AMPHOTERICIN_B_FLG+ 
                     
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                     TENOFOVIR_FLG+Total_DOT, x, dat) 
finmodel2lglm2<-glm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                      
factor(year)+factor(los_group)+DEHYDRATION_FLG+Total_DOT+nephrotoxic_dr
ug, x, dat) 
 
finmodel2lrm<-lrm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                    
factor(year)+factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCO
SIDES_FLG+ AMPHOTERICIN_B_FLG+ 
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ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                    TENOFOVIR_FLG+Total_DOT, dat) 
finmodel2lrm2<-lrm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                     
factor(year)+factor(los_group)+DEHYDRATION_FLG+Total_DOT+nephrotoxic_dr
ug, dat) 
 
 
dat$dc_date<-sapply(strsplit(dat$DISCHRG_DT, ' '),'[',1) 
dat$dc_date<-as.Date(dat$dc_date, format='%m/%d/%Y') 
dat$starttime<-0 
for(i in 1:nrow(dat)){ 
  if(dat$AKI[i]=='No AKI'){ 
    dat$stoptime[i]<-as.numeric(dat$dc_date[i]-dat$tx_index[i]) 
  } 
  if(dat$AKI[i]=='AKI'){ 
    dat$stoptime[i]<-as.numeric(dat$time_to_aki[i]) 
  } 
} 
 
for(i in 1:nrow(dat)){ 
  if(dat$AKI[i]=='No AKI'){ 
    dat$stoptime2[i]<-min(as.numeric(dat$tx_end[i]-dat$tx_index[i])+7, 
as.numeric(dat$dc_date[i]-dat$tx_index[i]) ) 
  } 
  if(dat$AKI[i]=='AKI'){ 
    dat$stoptime2[i]<-as.numeric(dat$time_to_aki[i]) 
  } 
} 
 
cxmod<-
coxph(S~group+factor(age_group)+nephrotoxic_drug+hypotension+DEHYDRATIO
N_FLG+ 
               
TOTAL_CHARLSON_SCORE+factor(baseline_crcl_group)+GENDER+factor(year), 
data=dat) 
 
dat_b<-dat 
dat$age_group<-as.factor(dat$age_group) 
treat<-with(dat, data.frame(group=levels(group),  
                            age_group=rep(levels(age_group)[1],3),  
                            
nephrotoxic_drug=rep('N',3),#rep(levels(nephrotoxic_drug)[1],3), 
                            hypotension=rep('N',3), 
                            DEHYDRATION_FLG=rep('N',3), 
                            
TOTAL_CHARLSON_SCORE=rep(mean(TOTAL_CHARLSON_SCORE),3), 
                            
baseline_crcl_group=rep(levels(baseline_crcl_group)[1],3), 
                            GENDER=rep("MALE",3), 
                            year=rep(levels(year)[1],3) 
                            #los_group=rep(levels(los_group)[1],3), 
                            #Total_DOT=rep(mean(Total_DOT),3) 
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)) 
plot(survfit(cxmod, newdata = treat),  
     col=c('red','blue', 'green'),  
     xlab='Days after treatment initiation', 
     ylab='Proportion without AKI',  
     conf.int=F) 
legend('bottomright', c('PTZ/VAN', 'PTZ', 'VM'),lty=1,col=c('red', 
'blue','green')) 
 
 
finmodel2glm<-glm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                     
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+ 
AMPHOTERICIN_B_FLG+ 
                     
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                     TENOFOVIR_FLG+Total_DOT, x, dat) 
 
finmodel2lrm<-lrm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                    
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+ 
AMPHOTERICIN_B_FLG+ 
                    
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                    TENOFOVIR_FLG+Total_DOT, dat) 
 
for(i in 1:nrow(dat)){ 
  if(dat$Total_DOT[i]<=3){ 
    dat$tdot_group[i]<-'2-3' 
  } 
  if(dat$Total_DOT[i]>=4 & dat$Total_DOT[i]<6){ 
    dat$tdot_group[i]<-'4-5' 
  } 
  if(dat$Total_DOT[i]>=6 & dat$Total_DOT[i]<8){ 
    dat$tdot_group[i]<-'6-7' 
  } 
  if(dat$Total_DOT[i]>=8 & dat$Total_DOT[i]<10){ 
    dat$tdot_group[i]<-'8-9' 
  } 
  if(dat$Total_DOT[i]>=10 & dat$Total_DOT[i]<12){ 
    dat$tdot_group[i]<-'10-11' 
  } 
  if(dat$Total_DOT[i]>=12 & dat$Total_DOT[i]<14){ 
    dat$tdot_group[i]<-'12-13' 
  } 
  if(dat$Total_DOT[i]>=14) 
    dat$tdot_group[i]<-'>=14' 
  } 
} 
dat$tdot_week<-dat$Total_DOT/7 
dat$tdot_group<-as.factor(dat$tdot_group) 
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dat$tdot_group<-relevel(dat$tdot_group, ref = '2-3') 
finmodel2glma<-glm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                    
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+ 
AMPHOTERICIN_B_FLG+ 
                    
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                    TENOFOVIR_FLG+ tdot_group, x, dat) 
finmodel2lrma<-lrm(aki_num~group + factor(age_group) + 
TOTAL_CHARLSON_SCORE+ factor(baseline_crcl_group)+ transfer+hypotension+ 
GENDER+ 
                     
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+ 
AMPHOTERICIN_B_FLG+ 
                     
ace.arb+tac.cyc+FOSCARNET_FLG+LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG
+SULFONAMIDES_FLG+ 
                     TENOFOVIR_FLG+tdot_group, dat) 
 
 
MODEL<-
glm(aki_num~group+factor(age_group)+TOTAL_CHARLSON_SCORE+factor(baselin
e_crcl_group)+transfer+hypotension+GENDER+ 
             
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMP
HOTERICIN_B_FLG+ANGIOTENSIN_FLG+ANGIOTENSION_FLG+ 
             TACROLIMUS_FLG+FOSCARNET_FLG+CYCLOSPORINE_FLG+ 
LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG+SULFONAMIDES_FLG+TENOFOVIR_FL
G+ 
             factor(tdot_group), x, dat) 
MODELlrm<-
lrm(aki_num~group+factor(age_group)+TOTAL_CHARLSON_SCORE+factor(baselin
e_crcl_group)+transfer+hypotension+GENDER+ 
             
factor(los_group)+DEHYDRATION_FLG+ACYCLOVIR_FLG+AMINOGLYCOSIDES_FLG+AMP
HOTERICIN_B_FLG+ANGIOTENSIN_FLG+ANGIOTENSION_FLG+ 
             TACROLIMUS_FLG+FOSCARNET_FLG+CYCLOSPORINE_FLG+ 
LOOP_DIURETICS_FLG+NON_STEROIDAL_ANTI_FLG+SULFONAMIDES_FLG+TENOFOVIR_FL
G+ 
             factor(tdot_group), dat) 
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2016; Boston, MA. 
 
Rutter WC, Burgess DS. In-Vitro Characterization of Amikacin and Polymyxin B 
Therapy in Combination with Meropenem for Carbapenem-resistant Enterobacter 
cloacae. Presented at ASM Microbe 2016; 16-20 June 2016; Boston, MA. 
 
Rutter WC, Talbert JC, Burgess DS. Incidence of Acute Kidney Injury in Patients 
Treated with Vancomycin and Piperacillin/Tazobactam. Presented at ID Week 2015; 7-
11 Oct 2015; San Diego, CA. 
 
Rutter WC, Burgess DS. Development of an Automated Process for Antibiogram 
Generation. Presented at ID Week 2015; 7-11 Oct 2015; San Diego, CA. 
 
Rutter WC, Burgess DR, Burgess DS. Increasing Incidence of Multidrug Resistance 
Among Cystic Fibrosis Respiratory Isolates. Presented at ID Week 2015; 7-11 Oct 2015; 
San Diego, CA. 
 
Rutter WC, Burgess DR, Burgess DS. Unit-specific Pharmacodynamic Modelling to Aid 
in Empiric Therapy Selection. Presented at ID Week 2015; 7-11 Oct 2015; San Diego, 
CA. 
 
Rutter WC, Talbert JC, Burgess DS. Factors Associated with Supratherapeutic 
Vancomycin Trough Concentrations in a Referral Center. Presented at ID Week 2015; 7-
11 Oct 2015; San Diego, CA. 
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Burgess DR, Rutter WC, Tennant SJ, Ribes J, Burgess DS. Antimicrobial Stewardship 
and the Use of Verigene ® Gram-Positive and Gram-Negative Rapid Identification 
System. Presented at ID Week 2015; 7-11 Oct 2015; San Diego, CA. 
 
Thompson RZ, Martin CA, Burgess DR, Rutter WC, Burgess DS. Optimizing Beta-
Lactam Pharmacodynamics Against Pseudomonas aeruginosa in Adult Cystic Fibrosis 
Patients. Presented at ID Week 2015; 7-11 Oct 2015; San Diego, CA. 
 
Cox JN, Rutter WC, Martin CA, Burgess DR, Zephyr D, Burgess DS. Incidence of 
Acute Kidney Injury During Therapy with Vancomycin in Combination with Beta-Lactam 
Antibiotics. Presented at ID Week 2015; 7-11 Oct 2015; San Diego, CA. 
 
Rutter WC, Burgess DS. Multiple methods of describing antimicrobial susceptibility: 
What do they tell us? Presented at Rho Chi Research Day, University of Kentucky; 17 
Apr 2015; Lexington, KY. 
 
Rutter WC, Burgess DS. In vitro characterization of amikacin and polymyxin b therapy 
in combination with meropenem for carbapenem-resistant Enterobacter cloacae. 
Presented at Rho Chi Research Day, University of Kentucky; 17 Apr 2015; Lexington, 
KY. 
 
Cox JN, Rutter WC, Martin CA, Burgess DR, Zephyr D, Burgess DS. Incidence of 
Acute Kidney Injury During Therapy with Vancomycin in Combination with Beta-Lactam 
Antibiotics. Presented at Rho Chi Research Day, University of Kentucky; 17 Apr 2015; 
Lexington, KY. 
 
Rutter WC, Wornall SH, Shely CL. Evaluation of MRSA treatment failures associated 
with elevated vancomycin minimum inhibitory concentrations in a rural, nonacademic 
hospital. Poster presented at: ASHP Midyear clinical meeting 2013; 11 Dec 2013; 
Orlando, FL. 
 
Rutter WC, Lee G, Burgess D, Winkler K, Burgess DS. Surveillance of resistance 
trends of community-acquired versus hospital-acquired urinary tract infections. Poster 
presented at: ASHP Midyear clinical meeting 2012; 3 Dec 2012; Las Vegas, NV. 
 
Rutter WC, Burgess D, Winkler K, Lee G, Burgess DS. Evaluation of epidemiology and 
susceptibility trends in urinary tract infections over 5 years in a community hospital. 
Poster presented at: IDWeek 2012. The 1st joint meeting of the Infectious Disease Society 
of America, the Society of Healthcare Epidemiology of America, the HIV Medicine 
Association, and the Pediatric Infectious Disease Society; 17-21 Oct 2012; San Diego, 
CA. 
 
Rutter WC, Lee G, Burgess D, Winkler K, Burgess DS. Surveillance of resistance 
trends of community-acquired versus hospital-acquired urinary tract infections. Poster 
presented at: IDWeek 2012. The 1st joint meeting of the Infectious Disease Society of 
America, the Society of Healthcare Epidemiology of America, the HIV Medicine 
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Association, and the Pediatric Infectious Disease Society; 17-21 Oct 2012; San Diego, 
CA. 
 
Rutter WC, Burgess D, Winkler K, Dasher T, Burgess DS. Evaluation of urinary tract 
infection antimicrobial susceptibility in a community hospital. Poster presented at: Eighth 
Annual Louis C. Littlefield Celebrating Pharmacy Research Excellence Day; 17 Apr 
2012; Austin, TX. 
 
SCHOLASTIC AND PROFESSIONAL HONORS      
11/2015 – Present  The Medicines Company Infectious Disease 
Pharmacotherapy Research Award 
 Society of Infectious Disease Pharmacists 
  
04/2013    Student Research/Scholarship Award 
    Graduate School of Biomedical Sciences – College of  
    Pharmacy 
 
05/2008 – 05/2013  The University of Texas at Austin – University Honors 
 
08/2010 – 08/2012  Pharmacy Alumni Association Endowed Scholarship  
 
08/2007 – 01/2008 The National Science & Mathematics Access to Retain 
Talent (SMART) Grant Recipient  
 
12/2006   The University of Texas at San Antonio – Dean’s List 
 
 
PROFESSIONAL SERVICE         
07/2013 – 06/2014  Pharmacy and Therapeutics committee 
   St. Claire Regional Medical Center 
 
10/2013  Medication administration Kaizen event team member 
   St. Claire Regional Medical Center  
